Parallax Volatility Advisers
PLX icon

Parallax Volatility Advisers’s Protalix BioTherapeutics PLX Stock Holding History

Parallax Volatility Advisers’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-7,000
Closed -$95K – 3506
2017
Q1 		$95K Buy
+7,000
New +$62.9K ﹤0.01% 2299

Other funds holding PLX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Parallax Volatility Advisers's PLX Position: Q3 2018 in Review

Parallax Volatility Advisers sold out of Protalix BioTherapeutics (PLX) in Q3 2018, closing a stake of 90 shares.

Parallax Volatility Advisers first reported a position in PLX in Q4 2016 and held it in 5 quarters. The position peaked at $63K in Q4 2016. 38 funds tracked by Wall St. Rank hold PLX as of Q3 2018.

  • Parallax Volatility Advisers reported no remaining Protalix BioTherapeutics position as of Q3 2018 after selling out during the quarter.
  • Parallax Volatility Advisers sold 90 Protalix BioTherapeutics shares in Q3 2018.
  • Parallax Volatility Advisers first reported a position in Protalix BioTherapeutics in Q4 2016 and held it in 5 quarters.
  • Parallax Volatility Advisers's Protalix BioTherapeutics position peaked at $63K in Q4 2016.
  • 38 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2018.

Based on Parallax Volatility Advisers's 13F filing for Q3 2018, filed 14 Nov 2018.